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content. TG F-tJ 1 gene expression is almost 3-fold increased in patients with
multiple vs single restenosis events in sapheneous vein grafts. Overall, ex-
tracellular neo-matrix formation was continuously increased over time.
strated the feasibility of very early noninvasive visualization of atherosclerotic
lesions with antibody-based scintigraphy.
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1803-31 Influence of Presence or Absence of Medial Necrosis
on Endothelial Regeneration and Intimal Hyperplasia
in the Rabbit Carotid Artery
18041 Treatment in Unstable Angina
Wednesday, March 22,1995,4:00 p.m.-5:00 p.m,
Ernest N, Morial Convention Center, La Louisiane B
Frits N. Doornekamp, Mark J. Post. Cornelius Borst. Heart Lung Institute, Utrecht
University Hospital, Utrecht, The Netherlands
Interventional injury induced intimal hyperplasia (IH) involves smooth muscle
cell proliferation which may be limited by endothelial cell (ECI regeneration.
We hypothesized that EC-regeneration (ECR) modulates IH. To create differ-
ent ECR's we induced EC removal with 100% media necrosis (2F Fogarty
balloon, 5 cm) and without media necrosis (prolene loop, 5 cm) in the rabbit
carotid artery. After termination at 3, 7, 21 or 42 days, the artery was di-
vided in segments which were alternately processed for paraffin- and frozen
sections. ECR was assessed with an antibody to CD31 and expressed as
percentage coverage. Proliferating cells were identified with an antibody to
the nuclear antigen Ki-67 and scored as percentage positive cells. The cross-
sectional IH area (IHA, mm2) was measured morphometrically from elastin
stained sections. Results: Wall coverage (%) with CD31 positive cells, IHA
(mm2) (mean ± sem, * = p < 0.05, , = P < 0.001, Fogarty balloon (BAL)
versus loop):
n ECR,3d ECR,7d ECR,2td ECRA2d IHA,7d IHA21d IHAA2d
BAL 7 3±2 57± 1461 ±5 82± 110.01 ±001 020±001' 026±0.03'
loop 7 8 ± 4 81 ± 10 93 ± 4 100 ± 0 0.01 ± 001 0.09 ± 004 0.08 ± 0.02
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Heparin Pretreatment May Confer Additional Benefit
in Patients Treated with 7E3 and PTCA for Unstable
Coronary Syndromes
Mark C.G. Horrigan, David S. Eccleston, Nancy M. Wildermann, Kristina
A Sigmon, Robert M. Califf, Eric J. Topol, EPIC Investigators. Cleveland Clinic
Foundation, Cleveland, OH; Duke University Medical Center. Durham, NC
Patients undergoing percutaneous intervention for unstable coronary syn-
dromes associated with coronary thrombus are at substantially increased
risk of ischemic complications. The incidence of ischemic complications in
the EPIC trial was reduced in this subgroup (n = 893) by treatment with
the chimeric monoclonal anti-lIbJIIla antibody 7E3. We assessed the clinical
effects of heparin pretreatment in this group. Data were available for 855 pa-
tients of whom 583 received 7E3 bolus or bolus and infusion. Of these, 383
(66%) were pretreated with heparin for a mean 55 hours [interquartile range
21, 96]. Outcomes examined included the primary 30 day composite end-
point (death, non-fatal infarction, CABG, repeat percutaneous intervention
for acute ischemia) components thereof and major bleeding events.
Pretreatment
'CvsA, 'Cvs B, ICvs B
1.8 (07, 43)
1.8 (08, 40)
1.3 (07, 2.8)
10(5.0%)
13(6.5%)
14(7.0%)
Primary endpOint 30 (7.8%) 25 (12.5%) 1.7 (0.9, 2.9)
Repeat percutaneous inter-
vention or CABG 11 (2.9%)
Myocardial infarction 14 (3.7%)
Major bleeding event 20 (5.2%)
Groups No Events Recurrent Angina AMI UI
G P P n P P
A 69 28(40%) 0.0002' 13(19%) 0.1 4(6%) 0.3 1(1%) 0.6
B 69 27 (39%) 0.00001' 18(26%) om l 1(1%) 3(4%)
C 67 49 (73%) 6(9%) 0 0
We report a randomized prospective single blind study to test if low molecu-
lar weight heparin (LMWH) in a high dose (214IC/kg anti-Xa, b.Ld.) by subcu-
taneous injection may achieve a potential benefit over regular heparin (RH)
and or aspirin to reduce silent events and its complications. A total of 205
patients with angina at rest in the last 24 hrs before admission entered the
study. Patients were monitored using a 2 channel device provided with an
alarm signal system during the first 48 hrs and randomized to aspirin in a
dose of 200 mg (Group A), aspirin plus RH (400 IU/kg/day Lv. trited by aPIT
[Group B]) and aspirin plus LMWH (Group C). The end points were: (1) free
of silent and symptomatic events; (2) recurrent angina, (3) AMI, (4) urgent
intervention ([Ull PTCA or CABG), (5) major bleeding and (6) death. A total of
8234 hrs were recorded appropriately. Events rates were tested by two-tailed
chi-square:
There was a strong trend toward further reduction of ischemic endpoints
when patients received heparin pretreatment in addition to 7E3. This ef-
fect was not associated with an increased incidence of significant bleeding.
These data support further investigation of the potentially additive roles of
anti-platelet and anti-thrombotic treatments as adjuncts to percutaneous in-
tervention in unstable coronary syndromes.
Heparin (n = 383) No heparin (n = 200) Odds ratio (95% CI)
Minor bleeding was detected in 10 cases in group Band 1 in C(p = 0.006).
There was only 1 major bleeding in group B and no deaths in any group.
Conclusions: In this study, treatment with LMWH in a high dose plus aspirin
reached significantly belter results than aspirin alone or aspirin plus RH.
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1804-21 Low Molecular Weight Heparin, Regular Heparin or
Aspirin to Treat Silent Ischemia in Unstable Angina
Enrique Gurfinkel, Ricardo Mejall, Eustaquio Manos, Miguel Cerda,
Ernesto Duranto, Claudio Garcia, Ana Daroca, Branco Mautner. Institute of
Cardiology and Cardiovascular Surgery, Favaloro Foundation, Buenos Aires, Argentina
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Very Early Noninvasive Visualization of Experimental
Atherosclerosis with Chimeric Antibody Z2D3
Radiolabeled with In-111 via Negatively-Charged
Chelating Polymer, or Tc·99m via Glucarate
Transchelation
From 3-42 days, ECR was enhanced in loop versus balloon injured arteries
(P < 0.001, ANOVA). At 3 and 7 days, more medial proliferation was found
after balloon than after loop injury (3d: 46.2 ± 8.8% versus 0.2 ± 0.1 %, 7d:
18.5 ± 6.4% versus 1.0 ± 0.4%; p < 0.01, ANOVA). In the same period,
abundant adventitial proliferation was found after balloon injury which was
entirely absent after loop injury.
Conclusion: Endothelial cell regeneration is slower over a damaged than
over a normal media. This retarded endothelial cell regeneration may con-
tribute to enhanced intimal hyperplasia.
Jagat Narula, Artiom Petrov, Charles Ditlow, Francis Chen, Chris Pak, Ban-An Khaw.
Northeastern University & Massachusetts General Hospital. Boston, MA; Scotgen
Biopharmaceuticallnc., Menlo Park, CA
We had reported the feasibility of noninvasive imaging of experimen-
tal atherosclerotic lesions with Indium-ll1-labeled mouselhuman chimeric
Z2D3 F(ab')2 specific for proliferating smooth muscle cells in human
atheroma. Lesions were visualized by 48 H. To reduce the delay between
visualization and antibody administration, (i), Z2D3 F(ab'h was labeled with
In-ll1 via negatively-charged chelating polymers (specific activity 500-1300
MBq/mg) and compared to the conventionalln-lll labeled counterpart (spe-
cific activity 32-48 MBq/mg); and (ii), Z2D3 Fab' was labeled with Tc-99m via
a weak transchelator, glucaric acid.
In vivo targeting was evaluated in 16 rabbits with atherosclerotic lesions
induced by infradiaphragmatic balloon deendothelialization of the abdominal
aorta followed by hyperlipidemic diet for 12 weeks. Four rabbits received 24
MBq (50 I'g) of In-ll1-<:harge modified Z203 F(ab')2' Two rabbits received
130 MBq (100 I'g) of the kit formulation of this preparation. Six rabbits re-
ceived 24 MBq (500-750 I'g) of conventional Z2D3 F(ab')2. The remaining 4
animals received Tc-99m Z203 Fab' (500-600 Mbq/375 I'g). Gamma imaging
revealed unequivocal tracer uptake in the abdominal atherosclerotic lesions
at 24 H in all 4 animals injected with modified Z2D3. In 2 rabbits with higher
specific radioactivity, the lesions could be visualized at 3 H. The blood pool
activity in rabbits injected with the conventional Z2D3 did not permit defini-
tive visualization of the lesions before 48 H. Blood clearance was significantly
faster with modified Z2D3 (0.10 ± 0.008, Mean %IO/g ± SEM), as compared
to the conventional Z2D3 (0.29 ± 0.04; P < 0.01). Uptake of modified Z2D3
preparations in atherosclerotic lesions at 24 H (0.08 ± 0.01) was similar to
the conventional Z2D3 at 48 H (0.08 ± 0.02; P = NS). Tc-Fab' localization was
visualizable at 12 H after administration of antibody. The Tc-Fab' uptake in the
atherosclerotic lesion was significantly higher in the lesion (0.022 ± 0.004)
compared to the normal {0.013 ± 0.002; p = 0.041 aorta. This study demon-
